trial summary · NCT07725523
Safety and Efficacy of OTL78
Safety and Efficacy of OTL78, a PSMA-targeted Fluorescent Agent, for Intraoperative Imaging of Prostate Cancer: A Phase IIb Trial Randomized Trial
Trial record from the TrialBase DB dataset, status RECRUITING, condition Prostate Cancer Surgery, sponsored by Clinton Bahler. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
This is a trial to assess the accuracy of an imaging agent, PSMA targeted fluorescent dye OTL78 (zopocianine), in combination with Near InfraRed (NIR) fluorescent imaging, to improve the detection of malignant (growing in an uncontrolled way) tissue in adult patients undergoing standard of care prostatectomy and lymph node dissection for biopsy confirmed prostate cancer. This trial is intended to confirm results from previous Phase 2 dose finding studies and to support the dose selection for subsequent Phase 3 development.
Source record: https://clinicaltrials.gov/study/NCT07725523
Facts
| registry id | NCT07725523 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE2/PHASE3 |
| study type | INTERVENTIONAL |
| lead condition | Prostate Cancer Surgery |
| sponsor | Clinton Bahler |
| sponsor class | OTHER |
| enrollment | 45 |
| start date | 2026-12 |
| primary completion | 2027-07 |
| completion | 2027-09 |
| results posted | not reported |
Conditions
- Prostate Cancer Surgery
- Prostate Cancer Metastatic Disease
Interventions
- 0.06 mg/kg ZOPOCIANINE given 1-7 days prior to surgery
Countries
- United States
Intervention types: DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.